Masanori Yokono

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
No aliases are listed.
Publication record
19 papers · 1,068 citations · H-index 10

PAPERS

Melatonin induces urethral contraction and increases intraurethral pressure via MT1 receptor activation in female rats.
20253 citationsauthor #6
Urethral function and histopathology in aged female rats as a stress urinary incontinence model
201910 citationsauthor #7
In Vitro Pharmacological Profile of Ipragliflozin, a Sodium Glucose Co-transporter 2 Inhibitor.
201910 citationsauthor #2
Effect of ASP2205 fumarate, a novel 5-HT2C receptor agonist, on urethral closure function in rats.
20196 citationsauthor #6
Antidiabetic and antiobesity effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed sugar solution
20188 citationsauthor #3
Characterization and comparison of SGLT2 inhibitors: Part 3. Effects on diabetic complications in type 2 diabetic mice
201745 citationsauthor #3
Effects of the combination of SGLT2 selective inhibitor ipragliflozin and various antidiabetic drugs in type 2 diabetic mice
20169 citationsauthor #3
Functional imaging of pharmacological action of SGLT2 inhibitor ipragliflozin via PET imaging using 11C‐MDG
20167 citationsauthor #5
Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects.
2016127 citationsauthor #3
Characterization and comparison of sodium-glucose cotransporter 2 inhibitors: Part 2. Antidiabetic effects in type 2 diabetic mice.
201632 citationsauthor #3
Effects of the combination of SGLT2 selective inhibitor ipragliflozin and various antidiabetic drugs in type 2 diabetic mice
20150 citationsauthor #3
Effects of sodium‐glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin‐induced type 1 diabetic rats
2014118 citationsauthor #3
SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats.
2014184 citationsauthor #1
Pharmacological Characterization of YM543, a Newly Synthesized, Orally Active SGLT2 Selective Inhibitor
20134 citationsauthor #1
Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice.
2013289 citationsauthor #3
Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice.
201234 citationsauthor #3
Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo
2011112 citationsauthor #3
Derive de phenylthiazole
20070 citationsauthor #9
Antagonism of peroxisome proliferator-activated receptor gamma prevents high-fat diet-induced obesity in vivo.
200671 citationsauthor #4

TIMELINE

2006 71 citations

2007 0 citations

2011 112 citations

2012 34 citations

2013 293 citations

2014 302 citations

2015 0 citations

2016 175 citations

2017 45 citations

2018 8 citations

2019 26 citations

2025 3 citations

Masanori Yokono

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT